Market Report ◆ bsab-mr

Bispecific Antibody Market ReportDRAFT

Version BsAb-MR-2026Q3Scope BsAb · Oncology + Autoimmune

12Chapters · 章节

538Census trials · 普查试验

5Golden Pairs · 黄金配对

61.7%TCE share · TCE 占比

About · 简介

Intelligence-led deep-dive on the bispecific antibody market: pipeline census, TCE analysis, target pairs, autoimmune & other therapeutic areas, deals, failures and tool-demand mapping.

Executive Summary — Three Judgments

Market growth is driven by expansion of head assets, not new targets (Top-10 assets = 72.7% of the 538-trial census).
TCE is the largest mechanism cluster (61.7%); tool demand is shifting from commoditized CD3ε reagents to differentiated gaps (CD3δ monomer, full-length DLL3 ECD, anti-LGR5).
Approval ≠ win — differentiation lies in earlier-line moves, generational formats and biomarkers.

Chapters · 章节

Data · 配套数据

census CSV · summary · readout calendar · TCE format shares — see bsab-market-report/data/ (Grade A, clinicaltrials.gov). Full evidence ledgers in gp-master/. Report status: DRAFT — pending founder review (#29).